MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma

RAS proto-oncogene specifically plays a crucial role in the transduction of growth-promoting signals and cellular proliferation (6). [...]activation of this MAPK signaling pathway is one of the most significant with respect to cell differentiation which subsequently leads to the desired biotic events. [...]atypical cellular activity (such as cell proliferation, angiogenesis, invasion and metastasis) occur innon-small lung cells. [...]another second-generation MEK inhibitor (PD0325901) has entered clinical trials; and thankfully, it has displayed better therapeutic activity and pharmaceutical properties than PD184352 (11,16). Based on this and because of the documented activation of the MEK pathway in NSCLC, MEK is still considered as an effective objective for NSCLC. [...]LGX818 is a BRAF inhibitor, which inhibits the proliferation of the malignancy cell line by blocking multi-signaling pathways such as ERK phosphorylation, RAF kinase inhibitors and mTOR inhibitors.